No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DGX240621P140000
- 2.33
- -0.95-28.96%
15min DelayClose May 31 16:00 ET
2.33High2.00Low
2.20Open3.28Pre Close24 Volume518 Open Interest140.00Strike Price5.24KTurnover19.50%IV-2.46%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry2.33Time Value100Contract SizeAmericanOptions Type-0.3492Delta0.0587Gamma93.10Leverage Ratio-0.0554Theta-0.0230Rho-32.51Eff Leverage0.1204Vega
Intraday
- 5D
- 1D
News
Express News | Study Finds CtDNA Testing For Minimal Residual Disease Can Cut Costs By 21% For Health Plans When Used For Stage II Colorectal Cancer Treatment Decisions
Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery...
Express News | NYSE Order Imbalance 162354.0 Shares on Buy Side
Quest Diagnostics Is Maintained at Neutral by JP Morgan
Quest Diagnostics Is Maintained at Neutral by JP Morgan
Quest Diagnostics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 11.68% JP Morgan $152 → $155 Maintains Neutral 04/25/2024 3.75% Barclays $138 → $144 Maintains
JPMorgan Adjusts Price Target on Quest Diagnostics to $155 From $152
Quest Diagnostics (DGX) has an average outperform rating and a price target range of $136 to $160, according to analysts polled by Capital IQ.
Comments
$Quest Diagnostics(DGX.US$ PathAI + Invigorate + stable finance + qualified management team + decent PE.
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
4
Quest Diagnostics' consistent ROCE and increased capital employed over the past five years suggest steady reinvestment at good returns. This trend, reflected in the stock's strong performance, is expected to continue.
The acquisition aligns with Quest's strategy to grow through accretive outreach laboratory acquisitions and expands its ability to serve providers and patients in Ohio and Pennsylvania.
The CEO of Quest Diagnostics, Jim Davis, believes Yuri Fesko's deep medical expertise and patient-care advocacy will greatly contribute to the company's strategic decisions. His appointment especially bolsters Quest's efforts to improve customer experiences via diagnostic innovations.
Quest Diagnostics shows favorable metrics with robust reinvestment strategies. Significant earnings growth and an anticipated rise in future ROE, despite a higher payout ratio, hint at other growth factors.
Read more